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conditions. Noteworthy, in a previous study, we 
showed that compared with the general popu‑
lation, the observed survival of dual ‑chamber 
(DDD) pacemaker recipients was significantly 
inferior until 12 years post implant, while af‑
ter 12 years of follow ‑up, the observed survival 
was significantly higher.2 Death rates alone do 
not provide a complete picture of the burden 
that deaths impose on the population. Anoth‑
er useful measure, which has been gaining in‑
creasing popularity in epidemiological reports, 
INTRODUCTION As shown in the FOLLOW‑ 
‑PACE study by Udo et al,1 pacemakers implant‑
ed for slow heart rhythm restore life expectan‑
cy to normal levels. The results have suggested 
that the prognosis of a contemporary patient 
with a pacemaker was primarily determined by 
concomitant cardiovascular disease, and not 
by the rhythm disorder itself. Therefore, after 
pacemaker implantation for bradycardia, more 
attention should be paid to the detection and 
treatment of other concurrent cardiovascular 
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ABSTRACT
BACKGROUND Pacemakers have become the standard of care in patients with severe bradycardia and 
conduction abnormalities. The survival and premature mortality can be assessed using the years of life 
lost (YLLs).
AIMS The aim of the study was to analyze mortality trends over the period from 1999 to 2015 among 
patients implanted with a dual ‑chamber (DDD) pacemaker who were inhabitants of Małopolska Province.
METHODS This was a retrospective study of records collected from consecutive patients who underwent 
de novo DDD pacemaker implantation at a single center between 1984 and 2014. Inclusion criteria were 
residence status in Małopolska Province at the latest follow ‑up visit and death between 1999 and 2015. 
The standard expected years of life lost per death was used to calculate YLLs. Time trends were evaluated 
with joinpoint models and presented as an average annual percentage change (AAPC).
RESULTS Among a total of 3932 consecutive patients implanted with a DDD pacemaker, 1211 patients 
met the inclusion criteria. We noted an increase in the mean age at implant from 70 years in 1999 to 75.5 
years in 2015 (AAPC, 0.6%; P <0.05), the number of years lived after DDD pacemaker implantation from 
2.6 years to 8.2 years (AAPC, 7.4%; P <0.05), and the mean age at death from 72.6 years to 83.8 years 
(AAPC, 0.89%; P <0.05). Finally, we observed a reduction of the YLLs per death from 17.4 years in 1999 to 
9 years in 2015 (AAPC, –4%; P <0.05). All trends were significant for both men and women.
CONCLUSIONS In the 17‑year follow ‑up, we showed significant changes in analyzed trends, in particular 
a reduction in the YLLs per death.
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Methodology and Applications Branch, Surveil‑
lance Research Program, National Cancer Insti‑
tute, Bethesda, Maryland, United States, 2014). 
This method is an advanced version of linear re‑
gression, where the time trend is expressed with 
a broken line, which is a sequence of segments 
joined in Joinpoint. To confirm whether the chang‑
es were significant, the Monte Carlo permutation 
method was applied. We estimated the annual per‑
centage change (APC) of the variables for each seg‑
ment of the segmented regression curve, average 
annual percentage change (AAPC) as a summary 
measure of trend that applies over an entire time 
period, and their 95% confidence intervals (CIs). 
When the trend is constant over the entire peri‑
od of interest, the AAPC will be equal to the esti‑
mated APC.5 In all analyses, a P value of less than 
0.05 was considered significant.
For YLL calculation, we used the standard 
expected years of life lost per death (SEYLLs) 
measure. It was used to calculate the number 
of YLLs by the studied population in compari‑
son with the YLLs by the standard population. 
The SEYLL weighs mortality, age at death, and 
the population structure, counts all life years 
lost at all ages, as well as weighs death by the re‑
sidual life expectancy in a standard life table. In 
the present study, the SEYLL index was calcu‑
lated according to the Marshall method and ex‑
pressed as a rate per a single death6:
k
SEYLL = ∑ daea
a = 0
where a denotes age at death; k, age of the oldest 
deceased patient; da number of patients deceased 
at the age of a; and ea number of expected years 
of life for a person at the age of a. The number 
of expected years of life (ea) for a person at the 
age of a was calculated based on the standard 
life table presented by Murray et al7 in the Glob‑
al Burden of Disease Study 2010.
RESULTS Out of 3932 patients, 3928 (99.9%) 
had known survival status. At the time of the last 
follow ‑up visit, 3702 patients (94.2%) were in‑
habitants of Małopolska Province. Among the in‑
habitants of this province, 1211 patients (32.7%) 
died between 1999 and 2015, including 696 men 
(57.5%) and 515 women (42.5%) (TABLE 1). Out of 
226 inhabitants of other provinces, 69 patients 
died. During follow ‑up, 7 of the 1211 patients had 
a device upgrade to an implantable cardioverter‑
‑defibrillator, 8 patients had an upgrade to cardi‑
ac resynchronization therapy pacemaker, and 3 
patients had an upgrade to cardiac resynchroni‑
zation therapy defibrillator. We observed an in‑
crease in the mean age at the time of implanta‑
tion from 70 years in 1999 to 75.5 years in 2015 
(AAPC, 0.62%; 95% CI, 0.4%–0.9%; P <0.05): in 
women, from 75.2 to 76.7 years (AAPC, 0.29%; 
is the years of life lost (YLLs). This less conven‑
tional indicator may add a different dimension 
to mortality trends in a population, in particular 
with regard to premature mortality. According to 
Eurostat, the YLL is the mortality component of 
the disability‑adjusted life years, introduced by 
the World Bank and the World Health Organiza‑
tion as a description of the “burden of disease.” 
The YLL ignores morbidity, and therefore only 
describes “the burden of mortality.”3 The aim 
of the study was to use the YLL measure to an‑
alyze mortality trends in the period from 1999 
to 2015 among inhabitants of Małopolska Prov‑
ince who were implanted with a DDD pacemaker.
METHODS This was a retrospective study of re‑
cords collected from consecutive patients who un‑
derwent primary DDD pacemaker implantation 
at a high ‑volume tertiary reference implantation 
center between October 4, 1984, and December 
31, 2014. Detailed methods of data collection and 
the baseline characteristics of the study popu‑
lation were presented previously.2,4 The inclu‑
sion criteria were residence status in Małopolska 
Province at the time of the last pacemaker follow‑
‑up visit and death between January 1, 1999, 
and December 31, 2015. Małopolska Province 
came into being on January 1, 1999. The data on 
the survival status of patients and the dates of 
death of deceased patients were collected from 
the national death registration system in 2016. 
The data used in the analysis included: 1) base‑
line demographic characteristics of patients: date 
of birth, age at implantation, and sex; 2) place of 
residence during follow ‑up; and 3) date of death 
declared in the death certificate. The following 
time trends were analyzed: 1) YLLs per 1 death; 
2) mean age at the time of death; 3) mean age 
at pacemaker implantation; and 4) mean time 
from implantation to death.
Statistical analysis Time trends of analyzed 
variables were evaluated using the Joinpoint Re‑
gression software developed by the Surveillance, 
Epidemiology and End Results program of the Na‑
tional Cancer Institute (Joinpoint Regression Pro‑
gram, Version 4.1.1.1. October 2014; Statistical 
WHAT’S NEW?
We investigated the lifespan of dual ‑chamber (DDD) pacemaker recipients 
living in Małopolska Province, Poland. We performed a trend analysis of age 
at implantation, survival after implantation, and age at death between 1999 
and 2015. Furthermore, we evaluated premature mortality by calculating 
the years of life lost over a 17‑year follow‑up. The results demonstrated 
a continuous improvement in the survival after DDD pacemaker implantation 
and a significant reduction of the years of life lost. To our knowledge, this is 
the first report adopting an accurate and comprehensive measure that quantifies 
the level and trend of premature mortality in patients with permanent 
pacemaker.
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pacemaker insertion calculated as AAPC was 
7.4% (95% CI, 4.2%–10.7%; P <0.05) in the whole 
study group, 8.2% (95% CI, 5%–11.5%; P <0.05) in 
women, and 6.3% (95% CI, 1.7%–11.1%; P <0.05) 
in men. Among women who died between 1999 
and 2003 and men who died between 1999 and 
2001, the APC of postimplant survival reached 
34.2% (95% CI, 19.4%–50.8%; P <0.05) and 34.3% 
(95% CI, –7.7% to 95.5%; P >0.05), respective‑
ly. For women who died between 2004 and 2015 
and for men who died between 2002 and 2015, 
the APC was lower and amounted to 0.7% (95% CI, 
–1.4% to 3%; P >0.05) and 2.8% (95% CI, 1%–4.6%; 
P <0.05), respectively (FIGURE 2).
The mean age at the time of death increased 
at a rate of 0.9% (95% CI, 0.7%–1%; P <0.05); 
0.6% (95% CI, 0.4%–0.8%; P <0.05) for wom‑
en and 1% (95% CI, 0.6%–1%; P <0.05) for men. 
The mean age of deceased pacemaker recipients 
in 1999 was 72.6 years (77.6 years in women 
and 71.2 years in men), whereas in 2015, it was 
83.8 years (84 years in women and 83.5 years in 
men) (FIGURE 3). Finally, we observed a decrease in 
YLLs per death with an AAPC of –4% (95% CI, 
–4.9% to –3.1%; P <0.05): for women, –2.9% (95% 
CI, –3.9% to –2%; P <0.05), and for men, –4.2% 
(95% CI, –5.2% to –3.1%; P <0.05). The YLLs per 
death in 1999 amounted to 17.4 years (13.3 in 
women and 18.6 in men), whereas in 2015, the 
value dropped to 9 (8.8 in women and 9.2 in 
men) (FIGURE 4).
DISCUSSION In this study, we demonstrated 
trends over the 17‑year period (1999–2015) in 
the characteristics and outcomes of DDD pace‑
maker recipients living in Małopolska Province 
in Poland. We observed shifts toward DDD pace‑
maker implantation at an older age, extended 
longevity after primary implant, and reduction 
in the YLLs per death. Furthermore, we noted 
that the APC of YLL reduction was greater in 
men than in women. Our findings provide ro‑
bust evidence for trends in demographics and 
survival among a large group of DDD pacemak‑
er recipients.
Few studies have investigated the epidemiol‑
ogy of patients with dual ‑chamber pacing. Our 
previous findings demonstrated that women 
were older than men at the time of pacemaker 
implantation and that an average age at implant 
increased over the 3 decades. Similar trends 
95% CI, 0.1%–0.5%; P <0.05); in men, from 68.6 
to 74.2 years (AAPC, 0.72%; 95% CI, 0.4%–1%; 
P <0.05) (FIGURE 1).
In the period from 1999 to 2015, we observed 
a prolonged life span after primary DDD pace‑
maker implantation, both for women and men. In 
1999, the survival after pacemaker implantation 
was 2.6 years (2.4 years in women and 2.7 years 
in men), whereas in 2015, it reached 8.2 years 
(7.3 years in women and 9.3 years in men). The av‑
erage rise in the number of survived years after 
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FIGURE 1 Age at the time of primary DDD pacemaker implantation
 Abbreviations: APC, annual percentage change
FIGURE 2 Average lifespan following DDD pacemaker implantation
 Abbreviations: see FIGURE 1
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TABLE 1 Number of patients meeting the study inclusion criteria
Sex Year
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Total
Women 6 6 13 11 7 13 19 22 21 31 29 32 53 65 54 60 73 515
Men 22 19 17 22 19 23 27 28 43 50 55 49 55 57 72 73 65 696
Total 28 25 30 33 26 36 46 50 64 81 84 81 108 122 126 133 138 1211
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changes reflecting Poland’s progress between 
1999 and 2015.
The study by the Global Burden of Disease 2017 
sheds some light on global and regional changes 
in mortality between 1980 and 2017.16 In general, 
YLL rates decreased while a sociodemographic in‑
dex for a given region increased. The total num‑
ber of deaths due to noncommunicable diseas‑
es, including both cardiovascular diseases and 
neoplasms, has risen steadily since 1990, driv‑
en by aging and population growth, while death 
and YLL rates have been falling consistently as 
a result of improvements in prevention strate‑
gies and healthcare. In Poland, the observed life 
expectancy between 2000 and 2017 rose from 
78 to 81.8 years for women and from 69.6 to 
74.1 years for men.17 Noncommunicable diseas‑
es contributed to 76.9% of YLLs among men and 
87.5% of YLLs among women in 2000.18 The to‑
tal all ‑cause mortality rate for the age group of 
70 years or older in 1999 was 7273 deaths per 
100 000, and in 2015, it dropped to 6361 deaths 
per 100 000. The rate of deaths attributable to 
cardiovascular diseases in this population de‑
creased from 4226 deaths per 100 000 in 1999 to 
3215 deaths per 100 000 in 2015. Between 2000 
and 2014, the rates of the YLLs per death due to 
cardiovascular diseases dropped, with an AAPC 
of –0.5% among men and –1.4% among women.19 
In the present study, the pace of decline in YLLs 
per death was significantly higher, with an AAPC 
of –4.2% for men and of –2.9% for women across 
the 17‑year follow ‑up. This remarkable difference 
may be explained by close and mostly life ‑long 
follow ‑up of pacemaker recipients by highly spe‑
cialized cardiologists in a tertiary reference cen‑
ter that provides comprehensive cardiac and car‑
diothoracic care and access to other medical and 
surgical facilities.
Interestingly, the observed significant rise in 
the lifespan after implant in women between 
1999 and 2003, with an APC over 34%, corre‑
sponded to a significant drop in the SEYLL per 
living person due to chronic noncommunicable 
diseases among the inhabitants of Poland in 
the period from 2000 to 2003.18 The trend for 
men in the period from 1999 to 2001 was not 
significant, most likely due to the small sam‑
ple. Since 1990, the 2 leading causes of death in 
Poland have continued to be ischemic heart dis‑
ease and stroke. Noteworthy, the rate of YLLs 
per death secondary to ischemic heart disease 
decreased significantly in the years 2000 to 
2014, with an AAPC of –1% for men and –1.2% 
for women, while the rate of YLLs per death sec‑
ondary to cerebrovascular diseases decreased 
at a pace of –0.5% for men and –1.3% for wom‑
en.19 On the other hand, the number of YLLs 
has increased for lung cancer, colorectal cancer, 
and Alzheimer disease. Importantly, according 
to the Global Burden of Disease, the Health‑
care Access and Quality Index in Poland had 
have been observed in other countries.2,8-13 In 
the present study, we found that the average 
trend of an increasing age at implantation in 
men exceeded the trend observed in women, 
which has not been previously reported. A sig‑
nificant increase in the life expectancy of pace‑
maker recipients being implanted in the con‑
secutive decades was shown by Brunner et al.9 
On the contrary, Bradshaw et al8 concluded that 
the era of implantation was not an independent 
predictor of mortality after adjustment for age. 
Several authors have argued that the progno‑
sis of pacemaker recipients did not differ com‑
pared with the general population unless sig‑
nificant comorbidities were present.1,8,14,15 Of 
note, our findings show consistently increas‑
ing life expectancy after the implantation de‑
spite a gradually increasing age of pacemak‑
er recipients. To fully appreciate this obser‑
vation, we may need to look at it in a broad 
context of economic, cultural, and behavioral 
FIGURE 3 Average age at the time of death
 Abbreviations: see FIGURE 1
FIGURE 4 Years of life lost per death
 Abbreviations: see FIGURE 1
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significantly improved between 2000 and 2016, 
with an AAPC of 0.9%. This measure is based on 
risk ‑standardized mortality rates or mortality‑
‑to ‑incidence ratios from causes that, in the pres‑
ence of quality healthcare, should not result in 
death (also known as amenable mortality). Ad‑
ditionally, the changes in behavioral, metabolic, 
and occupational risk that occurred in Poland 
between 2007 and 2017 have resulted in low‑
er rates of deaths and disability due to tobacco 
smoking, dietary risks, hypertension, and hy‑
percholesterolemia, whereas high body mass in‑
dex and high fasting plasma glucose levels have 
contributed to more deaths and disability.
Our findings should be interpreted in the con‑
text of limitations imposed by a retrospective 
study design. Due to the lack of data on the cause 
of death, we were unable to perform compar‑
isons with the general population. Moreover, 
the results cannot be generalized to a general 
pacemaker population as our sample consisted 
only of DDD pacemaker recipients. In addition, 
we included only patients who were deceased and 
were inhabitants of Małopolska Province at the 
last follow ‑up visit and excluded patients who 
remained alive until 2015 or were inhabitants 
of other provinces. On the other hand, the life 
expectancy may vary across regions in Poland; 
therefore, by narrowing the sample down, we 
aimed to obtain the most accurate estimation 
of patients’ demographic characteristics and 
lifespan. Nonetheless, we believe that the abili‑
ty to generate locally representative estimates of 
demographic and survival trends in DDD pace‑
maker population is the strength of our study.
In conclusion, we identified a  shift to‑
ward favorable life expectancy and a  de‑
crease in the YLLs among DDD recipients in 
Małopolska Province. Many of the factors driv‑
ing that positive trend include state ‑of ‑the ‑art 
cardiology care during follow ‑up but also eco‑
nomic transformation, improvement in gener‑
al healthcare system, as well as behavioral and 
lifestyle changes observed in Poland.
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